Tekla Life Sciences Investors of Benef Interest
Name
As of 05/14/2024Price
Aum/Mkt Cap
YIELD
Exp Ratio
Watchlist
Vitals
YTD Return
-1.0%
1 yr return
-3.6%
3 Yr Avg Return
-7.8%
5 Yr Avg Return
-1.5%
Net Assets
$390 M
Holdings in Top 10
50.6%
52 WEEK LOW AND HIGH
Expenses
OPERATING FEES
Expense Ratio 1.24%
SALES FEES
Front Load N/A
Deferred Load N/A
TRADING FEES
Turnover 62.37%
Redemption Fee N/A
Min Investment
Standard (Taxable)
N/A
IRA
N/A
Fund Classification
Fund Type
Closed-end mutual fund
Name
As of 05/14/2024Price
Aum/Mkt Cap
YIELD
Exp Ratio
Watchlist
XHQLX - Profile
Distributions
- YTD Total Return -1.0%
- 3 Yr Annualized Total Return -7.8%
- 5 Yr Annualized Total Return -1.5%
- Capital Gain Distribution Frequency N/A
- Net Income Ratio -0.80%
- Dividend Yield 0.0%
- Dividend Distribution Frequency Quarterly
Fund Details
-
Legal NameTekla Life Sciences Investors of Benef Interest
-
Fund Family NameTekla Capital Management LLC
-
Inception DateNov 22, 2011
-
Shares Outstanding25144038
-
Share ClassOther
-
CurrencyUSD
-
Domiciled CountryUnited States
-
ManagerDaniel Omstead
Fund Description
XHQLX - Performance
Return Ranking - Trailing
Period | XHQLX Return | Category Return Low | Category Return High | Rank in Category (%) |
---|---|---|---|---|
YTD | -1.0% | -18.5% | 18.3% | 87.04% |
1 Yr | -3.6% | -19.9% | 22.3% | 87.65% |
3 Yr | -7.8%* | -29.4% | 12.8% | 89.68% |
5 Yr | -1.5%* | -4.8% | 15.8% | 97.81% |
10 Yr | 1.1%* | 0.2% | 13.9% | 98.13% |
* Annualized
Return Ranking - Calendar
Period | XHQLX Return | Category Return Low | Category Return High | Rank in Category (%) |
---|---|---|---|---|
2023 | -2.2% | -12.6% | 19.0% | 82.10% |
2022 | -15.6% | -53.9% | 3.2% | 74.19% |
2021 | -9.3% | -39.6% | 24.2% | 71.61% |
2020 | 10.9% | -13.6% | 178.2% | 62.91% |
2019 | 17.0% | 3.8% | 63.8% | 77.78% |
Total Return Ranking - Trailing
Period | XHQLX Return | Category Return Low | Category Return High | Rank in Category (%) |
---|---|---|---|---|
YTD | -1.0% | -18.5% | 18.3% | 87.04% |
1 Yr | -3.6% | -19.9% | 22.3% | 87.65% |
3 Yr | -7.8%* | -29.4% | 12.8% | 89.68% |
5 Yr | -1.5%* | -4.8% | 15.8% | 97.81% |
10 Yr | 1.1%* | 0.2% | 13.9% | 98.13% |
* Annualized
Total Return Ranking - Calendar
Period | XHQLX Return | Category Return Low | Category Return High | Rank in Category (%) |
---|---|---|---|---|
2023 | -2.2% | -12.6% | 19.0% | 88.27% |
2022 | -15.6% | -53.9% | 3.7% | 79.35% |
2021 | -9.3% | -33.9% | 26.0% | 88.39% |
2020 | 10.9% | -0.7% | 180.6% | 92.05% |
2019 | 21.6% | 4.6% | 63.8% | 79.26% |
NAV & Total Return History
XHQLX - Holdings
Concentration Analysis
XHQLX | Category Low | Category High | XHQLX % Rank | |
---|---|---|---|---|
Net Assets | 390 M | 7.41 M | 47.2 B | 58.02% |
Number of Holdings | 145 | 23 | 420 | 10.49% |
Net Assets in Top 10 | 247 M | 2.19 M | 20.5 B | 57.41% |
Weighting of Top 10 | 50.56% | 18.1% | 77.0% | 33.33% |
Top 10 Holdings
- Moderna Inc 7.94%
- Gilead Sciences Inc 7.64%
- Amgen Inc 6.91%
- Regeneron Pharmaceuticals Inc 5.61%
- Illumina Inc 5.02%
- Horizon Therapeutics PLC 4.83%
- Seagen Inc Ordinary Shares 4.64%
- Vertex Pharmaceuticals Inc 4.30%
- Alexion Pharmaceuticals Inc 4.15%
- Biogen Inc 4.00%
Asset Allocation
Weighting | Return Low | Return High | XHQLX % Rank | |
---|---|---|---|---|
Stocks | 91.87% | 87.17% | 106.13% | 89.51% |
Preferred Stocks | 7.86% | 0.00% | 7.86% | 0.62% |
Cash | 2.51% | 0.00% | 34.44% | 49.38% |
Convertible Bonds | 0.00% | 0.00% | 0.37% | 34.39% |
Bonds | 0.00% | 0.00% | 12.39% | 37.65% |
Other | -2.25% | -22.99% | 23.31% | 98.77% |
Stock Sector Breakdown
Weighting | Return Low | Return High | XHQLX % Rank | |
---|---|---|---|---|
Healthcare | 99.82% | 59.26% | 100.00% | 56.05% |
Financial Services | 0.18% | 0.00% | 1.60% | 16.56% |
Utilities | 0.00% | 0.00% | 0.00% | 29.30% |
Technology | 0.00% | 0.00% | 22.69% | 36.31% |
Real Estate | 0.00% | 0.00% | 5.89% | 33.12% |
Industrials | 0.00% | 0.00% | 7.02% | 35.03% |
Energy | 0.00% | 0.00% | 0.00% | 29.30% |
Communication Services | 0.00% | 0.00% | 9.11% | 32.48% |
Consumer Defense | 0.00% | 0.00% | 25.73% | 39.49% |
Consumer Cyclical | 0.00% | 0.00% | 1.92% | 35.03% |
Basic Materials | 0.00% | 0.00% | 7.16% | 52.23% |
Stock Geographic Breakdown
Weighting | Return Low | Return High | XHQLX % Rank | |
---|---|---|---|---|
US | 83.97% | 66.21% | 104.41% | 74.69% |
Non US | 7.90% | 0.00% | 28.58% | 29.63% |
XHQLX - Expenses
Operational Fees
XHQLX Fees (% of AUM) | Category Return Low | Category Return High | Rank in Category (%) | |
---|---|---|---|---|
Expense Ratio | 1.24% | 0.08% | 4.28% | 40.12% |
Management Fee | 0.98% | 0.03% | 1.25% | 90.12% |
12b-1 Fee | N/A | 0.00% | 1.00% | N/A |
Administrative Fee | N/A | 0.03% | 0.25% | N/A |
Sales Fees
XHQLX Fees (% of AUM) | Category Return Low | Category Return High | Rank in Category (%) | |
---|---|---|---|---|
Front Load | N/A | 3.50% | 5.75% | N/A |
Deferred Load | N/A | 1.00% | 5.00% | N/A |
Trading Fees
XHQLX Fees (% of AUM) | Category Return Low | Category Return High | Rank in Category (%) | |
---|---|---|---|---|
Max Redemption Fee | N/A | 1.00% | 1.00% | N/A |
Related Fees
Turnover provides investors a proxy for the trading fees incurred by mutual fund managers who frequently adjust position allocations. Higher turnover means higher trading fees.
XHQLX Fees (% of AUM) | Category Return Low | Category Return High | Rank in Category (%) | |
---|---|---|---|---|
Turnover | 62.37% | 0.00% | 238.00% | 78.99% |
XHQLX - Distributions
Dividend Yield Analysis
XHQLX | Category Low | Category High | XHQLX % Rank | |
---|---|---|---|---|
Dividend Yield | 0.00% | 0.00% | 6.24% | 56.79% |
Dividend Distribution Analysis
XHQLX | Category Low | Category High | Category Mod | |
---|---|---|---|---|
Dividend Distribution Frequency | Quarterly | Annual | Annual | Annual |
Net Income Ratio Analysis
XHQLX | Category Low | Category High | XHQLX % Rank | |
---|---|---|---|---|
Net Income Ratio | -0.80% | -2.54% | 1.85% | 83.87% |
Capital Gain Distribution Analysis
XHQLX | Category Low | Category High | Capital Mode | |
---|---|---|---|---|
Capital Gain Distribution Frequency | Annually | Semi-Annually | Annually |
Distributions History
Date | Amount | Type |
---|---|---|
May 30, 2019 | $0.370 | OrdinaryDividend |
Feb 27, 2019 | $0.330 | OrdinaryDividend |
Nov 27, 2018 | $0.420 | OrdinaryDividend |
Aug 27, 2018 | $0.400 | OrdinaryDividend |
May 31, 2018 | $0.400 | OrdinaryDividend |
Feb 27, 2018 | $0.400 | OrdinaryDividend |
Nov 27, 2017 | $0.430 | OrdinaryDividend |
Aug 24, 2017 | $0.420 | OrdinaryDividend |
May 30, 2017 | $0.410 | OrdinaryDividend |
Feb 24, 2017 | $0.360 | OrdinaryDividend |
Nov 23, 2016 | $0.400 | OrdinaryDividend |
Jun 21, 2016 | $0.820 | OrdinaryDividend |
Apr 21, 2016 | $0.370 | OrdinaryDividend |
Feb 26, 2016 | $0.480 | OrdinaryDividend |
Dec 28, 2015 | $0.710 | ExtraDividend |
Nov 23, 2015 | $0.470 | OrdinaryDividend |
Aug 26, 2015 | $0.580 | OrdinaryDividend |
May 22, 2015 | $0.540 | OrdinaryDividend |
Feb 26, 2015 | $0.500 | OrdinaryDividend |
Nov 24, 2014 | $0.470 | OrdinaryDividend |
Aug 27, 2014 | $0.450 | OrdinaryDividend |
May 23, 2014 | $0.430 | OrdinaryDividend |
Feb 27, 2014 | $0.420 | OrdinaryDividend |
Nov 25, 2013 | $0.400 | OrdinaryDividend |
Aug 27, 2013 | $0.350 | OrdinaryDividend |
May 23, 2013 | $0.340 | OrdinaryDividend |
Feb 27, 2013 | $0.300 | OrdinaryDividend |
Nov 19, 2012 | $0.310 | OrdinaryDividend |
Aug 20, 2012 | $0.300 | OrdinaryDividend |
May 21, 2012 | $0.290 | OrdinaryDividend |
Feb 17, 2012 | $0.260 | OrdinaryDividend |
Nov 17, 2011 | $0.640 | OrdinaryDividend |
Aug 19, 2011 | $0.270 | OrdinaryDividend |
May 20, 2011 | $0.260 | OrdinaryDividend |
Feb 16, 2011 | $0.250 | OrdinaryDividend |
Nov 18, 2010 | $0.230 | OrdinaryDividend |
Aug 19, 2010 | $0.130 | OrdinaryDividend |
May 20, 2010 | $0.160 | OrdinaryDividend |
May 20, 2009 | $0.200 | OrdinaryDividend |
Feb 18, 2009 | $0.220 | OrdinaryDividend |
Nov 19, 2008 | $0.260 | OrdinaryDividend |
Aug 20, 2008 | $0.260 | OrdinaryDividend |
May 21, 2008 | $0.270 | OrdinaryDividend |
Feb 20, 2008 | $0.310 | OrdinaryDividend |
Nov 19, 2007 | $0.310 | OrdinaryDividend |
Aug 20, 2007 | $0.290 | OrdinaryDividend |
May 23, 2007 | $0.290 | OrdinaryDividend |
Feb 20, 2007 | $0.280 | OrdinaryDividend |
Nov 17, 2006 | $0.280 | OrdinaryDividend |
Sep 06, 2006 | $0.290 | OrdinaryDividend |
Jun 07, 2006 | $0.350 | OrdinaryDividend |
Feb 16, 2006 | $0.320 | OrdinaryDividend |
Nov 17, 2005 | $1.090 | OrdinaryDividend |
Aug 18, 2005 | $0.330 | OrdinaryDividend |
May 24, 2005 | $0.310 | OrdinaryDividend |
Feb 17, 2005 | $0.330 | OrdinaryDividend |
Nov 18, 2004 | $0.320 | OrdinaryDividend |
Aug 18, 2004 | $0.339 | OrdinaryDividend |
May 21, 2004 | $0.360 | OrdinaryDividend |
Feb 18, 2004 | $0.340 | OrdinaryDividend |
Nov 24, 2003 | $0.340 | OrdinaryDividend |
Aug 07, 2003 | $0.330 | OrdinaryDividend |
May 15, 2003 | $0.280 | OrdinaryDividend |
Feb 18, 2003 | $0.290 | OrdinaryDividend |
Nov 20, 2002 | $0.900 | OrdinaryDividend |
Aug 07, 2002 | $0.340 | OrdinaryDividend |
May 21, 2002 | $0.430 | OrdinaryDividend |
Feb 15, 2002 | $0.510 | OrdinaryDividend |
Nov 16, 2001 | $1.580 | OrdinaryDividend |
May 08, 2001 | $0.450 | OrdinaryDividend |
Feb 14, 2001 | $0.540 | OrdinaryDividend |
Nov 20, 2000 | $2.370 | OrdinaryDividend |
Aug 21, 2000 | $0.720 | OrdinaryDividend |
May 19, 2000 | $0.620 | OrdinaryDividend |
Feb 17, 2000 | $0.450 | OrdinaryDividend |
Nov 16, 1999 | $0.080 | CapitalGainShortTerm |
Nov 16, 1999 | $1.090 | CapitalGainLongTerm |
Nov 20, 1998 | $0.280 | CapitalGainLongTerm |
Nov 19, 1997 | $0.740 | CapitalGainLongTerm |
Nov 14, 1996 | $1.640 | CapitalGainLongTerm |
XHQLX - Fund Manager Analysis
Managers
Daniel Omstead
Start Date
Tenure
Tenure Rank
Sep 30, 2001
20.68
20.7%
Omstead is president and chief executive officer of Tekla Capital Management, formerly known as Hambrecht & Quist Capital Management, Inc. Before joining the adviser, Omstead was president and CEO of Reprogenesis, Inc., a private development stage biotech company developing therapies in the field of regenerative medicine. Before joining Reprogenesis, he was senior vice president, research and development at Cytotherapeutics, Inc., a public biotech company that developed CNS therapies.
Tenure Analysis
Category Low | Category High | Category Average | Category Mode |
---|---|---|---|
0.02 | 24.72 | 7.87 | 22.1 |